Sensus Healthcare First Quarter 2022 Financial Results Feature Revenue Growth of 237% Diluted EPS from operations of $0.20 compare with $(0.07) in the year-ago quarter Affirms expectations for continued growth in the sec

Healthcare First Quarter 2022 Financial Results Feature Revenue Growth of 237%

EPS from operations of $0.20 compare with $(0.07) in the year-ago quarter

expectations for continued growth in the second quarter and full year profitability

call begins at 4:30 p.m. Eastern time today

RATON, Fla. (May 5, 2022) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective,

non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results

for the three months ended March 31, 2022.

from the first quarter of 2022 and recent weeks include the following (all comparisons are with the first quarter of 2021, unless otherwise

for the first quarter reflect a sharpened focus on our core dermatology business, and we are pleased with the revenue growth we continue

to achieve," said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. "During the quarter we sold our

non-core asset for $15.0 million in cash and recorded a gain on asset sale of $12.8 million. This cash will primarily be used to fund

future growth of our dermatology products and services. We launched TransDermal Infusion into the U.S. market which has tremendous potential

in eliminating the need for needle injections allowing for more procedure to be less painful for patients. Also, our board of directors

has approved a $3.0 million share repurchase program that we intend to deploy thoughtfully and in the best interest of our stockholders."

Sardano continued, "We established a fair market value leasing program in January 2021, which continues to be well received and

supported the sales growth of SRT-100 Vision systems. This product, with its premium functionality and image-guided ultrasound, now accounts

for the vast majority of domestic SRT system sales. The upward revaluation of reimbursement codes by the Centers for Medicare and Medicaid

Services has made the return on investment for our systems even more compelling. In addition, with increased sales of Vision systems

we are selling significantly more service contracts. Approximately one-half of our customers are now under Extended Warranty Service

Agreements, compared with just 25% a few years ago, providing Sensus with a growing base of recurring revenues.

resumption of in-person trade shows has been deeply gratifying. These events allow us to reconnect with customers, showcase our products

and build high-caliber sales leads. We were delighted to highlight our TransDermal Infusion System for non-invasive

drug delivery for skin rejuvenation treatments, pre-laser treatments and pre- and post-plastic surgery at the Winter Clinical in Hawaii,

and at the American Academy of Dermatology conference in Boston. We are excited about the potential for this system, in particular for

the delivery of finasteride, commonly known as Propecia, for hair growth. Dr. Glynis Ablon, a key opinion leading dermatologist with

the Ablon Skin Institute and Research Center, and Associate Clinical Professor at UCLA is studying the delivery of finasteride with our

TransDermal System. We believe her work will validate the system's excellent utility for this indication."

Sardano concluded, "During the first quarter we hired nine sales representatives, returning our sales organization to pre-pandemic

levels. We continue to be confident in our sales and earnings trajectory as supported by a robust organization, excellent products backed

by rigorous research, creative methods of financing and a committed management team. Despite current geopolitical events, we continue

to be highly optimistic about our prospects."

Quarter Financial Results

for the first quarter of 2022 were $10.3 million, compared with $3.1 million for the first quarter of 2021. The 237% increase was primarily

driven by a higher number of units sold, increased service revenue, and the impact of COVID-19 on first quarter of 2021 results.

of sales for the first quarter of 2022 was $3.2 million, compared with $1.5 million for the prior-year quarter. The increase was due

to higher sales in the 2022 period.

profit for the first quarter of 2022 was $7.1 million, or 69.1% of revenues, compared with $1.6 million, or 51.6% of revenues, for the

first quarter of 2021. The increases were primarily driven by the higher number of units sold in 2022, service revenue on installed units,

and the impact of COVID-19 on first quarter 2021 results.

and marketing expense for the first quarter of 2022 was $1.2 million, compared with $1.1 million for the first quarter of 2021. The increase

was primarily attributable to higher tradeshow expenses and commissions.

and administrative expense for the first quarter of 2022 was $1.3 million, compared with $1.0 million for the first quarter of 2021.

The increase was primarily due to higher professional fees and compensation expense.

and development expense for the first quarter of 2022 was $0.7 million, unchanged from the prior-year first quarter.

income was $12.8 million for the first quarter of 2022, which is related to the gain on the sale of assets.

for income taxes was $0.6 million for the first quarter of 2022, compared with no income tax provision for the prior-year first quarter.

income for the first quarter of 2022 was $16.1 million, or $0.97 per diluted share, compared with a net loss of $(1.1) million, or $(0.07)

per share, for the first quarter of 2021.

EBITDA for the first quarter of 2022 was $16.9 million, compared with $(0.8) million for the first quarter of 2021. Adjusted EBITDA,

a non-GAAP financial measure, is defined as earnings before interest, taxes, depreciation, amortization and stock-compensation expense.

Please see below for a reconciliation between GAAP and non-GAAP financial measures, and the specific reasons these non-GAAP financial

measures are provided.

and investments were $32.8 million as of March 31, 2022, compared with $14.5 million as of December 31, 2021. The company had no outstanding

borrowings under its revolving line of credit as of March 31, 2022 or December 31, 2021.

of Non-GAAP Financial Information

press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally

accepted in the United States (GAAP). Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure, in its analysis

of performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures, nor should it be viewed as a substitute

for operating results determined in accordance with GAAP. Management believes the presentation of Adjusted EBITDA, which excludes the

impact of interest, income taxes, depreciation, amortization and stock-compensation expense, provides useful supplemental information

that is essential to a proper understanding of the financial results of Sensus Healthcare. Non-GAAP financial measures are not formally

defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare. As a complement to

GAAP financial measures, management believes that Adjusted EBITDA assists investors who follow the practice of some investment analysts

who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort comparability. A reconciliation

of the GAAP net loss to Adjusted EBITDA is provided in the schedule below.

TO NON-GAAP RECONCILIATION

Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time, during which management will

discuss financial results for the first quarter of 2022, provide a business update and answer questions. To access the conference call,

please dial 888-390-3967 (U.S. and Canada) or 862-298-0702 (International). Please direct the operator to be connected to the Sensus

Healthcare conference call. The call will be webcast live and can be accessed at the following link, which also may be found in the Investor

Relations section of the Company's website at www.sensushealthcare.com.

the conclusion of the conference call, a replay will be available by dialing 888-539-4649 (U.S. and Canada Toll Free) or 754-333-7735

(International). At the system prompt, dial the replay code 157081 followed by the # sign. Playback will begin automatically. An archived

webcast of the call will also be available in the Investor Relations section of the Company's website for a period of time.

Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments

for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation

therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids

with its SRT-100 , SRT-100+ and SRT-100 Vision systems. With its portfolio of innovative

medical device products, including aesthetic lasers and its needleless TransDermal Infusion System , Sensus provides

revolutionary treatment options to enhance the quality of life of patients around the world.

more information, visit www.sensushealthcare.com.

press release includes statements that are, or may be deemed, "forward-looking statements." In some cases, these statements can be

identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects,"

"plans," "intends," "may," "could," "might," "will," "should,"

"approximately," "potential" or negative or other variations of those terms or comparable terminology, although

not all forward-looking statements contain these words.

statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry,

and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to

a greater or lesser degree than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained

in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial

condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements

contained in this press release, as a result of the following factors, among others: the continuation and severity of the COVID-19 pandemic,

including its impact on sales and marketing; our ability to achieve profitability; our ability to obtain and maintain the intellectual

property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property

rights of third parties; the level and availability of government and/or third party payor reimbursement for clinical procedures using

our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory

requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks

arising from our international operations; legislation, regulation, or other governmental action that affects our products, taxes, international

trade regulation, or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration